newsfilter
← Latest News
GlobeNewswire·

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces